A citation-based method for searching scientific literature

Patrick M O'Neil, Andreas L Birkenfeld, Barbara McGowan, Ofri Mosenzon, Sue D Pedersen, Sean Wharton, Charlotte Giwercman Carson, Cecilie Heerdegen Jepsen, Maria Kabisch, John P H Wilding. Lancet 2018
Times Cited: 167







List of co-cited articles
806 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
697
46

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
27

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Melanie J Davies, Richard Bergenstal, Bruce Bode, Robert F Kushner, Andrew Lewin, Trine Vang Skjøth, Arne Haahr Andreasen, Christine Bjørn Jensen, Ralph A DeFronzo. JAMA 2015
344
26

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
25

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
220
22


3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
Carel W le Roux, Arne Astrup, Ken Fujioka, Frank Greenway, David C W Lau, Luc Van Gaal, Rafael Violante Ortiz, John P H Wilding, Trine V Skjøth, Linda Shapiro Manning,[...]. Lancet 2017
241
18


MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Philip Ambery, Victoria E Parker, Michael Stumvoll, Maximilian G Posch, Tim Heise, Leona Plum-Moerschel, Lan-Feng Tsai, Darren Robertson, Meena Jain, Marcella Petrone,[...]. Lancet 2018
106
16

The Discovery and Development of Liraglutide and Semaglutide.
Lotte Bjerre Knudsen, Jesper Lau. Front Endocrinol (Lausanne) 2019
91
16

Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
John Blundell, Graham Finlayson, Mads Axelsen, Anne Flint, Catherine Gibbons, Trine Kvist, Julie B Hjerpsted. Diabetes Obes Metab 2017
95
14

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.
Robert F Kushner, Salvatore Calanna, Melanie Davies, Dror Dicker, W Timothy Garvey, Bryan Goldman, Ildiko Lingvay, Mette Thomsen, Thomas A Wadden, Sean Wharton,[...]. Obesity (Silver Spring) 2020
31
45

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Frank L Greenway, Ken Fujioka, Raymond A Plodkowski, Sunder Mudaliar, Maria Guttadauria, Janelle Erickson, Dennis D Kim, Eduardo Dunayevich. Lancet 2010
434
13

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Richard E Pratley, Vanita R Aroda, Ildiko Lingvay, Jörg Lüdemann, Camilla Andreassen, Andrea Navarria, Adie Viljoen. Lancet Diabetes Endocrinol 2018
200
13

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
Jesper Lau, Paw Bloch, Lauge Schäffer, Ingrid Pettersson, Jane Spetzler, Jacob Kofoed, Kjeld Madsen, Lotte Bjerre Knudsen, James McGuire, Dorte Bjerre Steensgaard,[...]. J Med Chem 2015
291
13

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
Anna Secher, Jacob Jelsing, Arian F Baquero, Jacob Hecksher-Sørensen, Michael A Cowley, Louise S Dalbøge, Gitte Hansen, Kevin L Grove, Charles Pyke, Kirsten Raun,[...]. J Clin Invest 2014
357
13

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
W Timothy Garvey, Jeffrey I Mechanick, Elise M Brett, Alan J Garber, Daniel L Hurley, Ania M Jastreboff, Karl Nadolsky, Rachel Pessah-Pollack, Raymond Plodkowski. Endocr Pract 2016
368
13

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Richard Pratley, Aslam Amod, Søren Tetens Hoff, Takashi Kadowaki, Ildiko Lingvay, Michael Nauck, Karen Boje Pedersen, Trine Saugstrup, Juris J Meier. Lancet 2019
128
13

Once-Weekly Semaglutide in Adults with Overweight or Obesity.
John P H Wilding, Rachel L Batterham, Salvatore Calanna, Melanie Davies, Luc F Van Gaal, Ildiko Lingvay, Barbara M McGowan, Julio Rosenstock, Marie T D Tran, Thomas A Wadden,[...]. N Engl J Med 2021
87
14

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
W Timothy Garvey, Donna H Ryan, Michelle Look, Kishore M Gadde, David B Allison, Craig A Peterson, Michael Schwiers, Wesley W Day, Charles H Bowden. Am J Clin Nutr 2012
329
12

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, George Abouda, Mark A Aldersley,[...]. Lancet 2016
705
12

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
Caroline M Apovian, Louis Aronne, Domenica Rubino, Christopher Still, Holly Wyatt, Colleen Burns, Dennis Kim, Eduardo Dunayevich. Obesity (Silver Spring) 2013
251
12


Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).
David B Allison, Kishore M Gadde, William Timothy Garvey, Craig A Peterson, Michael L Schwiers, Thomas Najarian, Peter Y Tam, Barbara Troupin, Wesley W Day. Obesity (Silver Spring) 2012
311
11

European Guidelines for Obesity Management in Adults.
Volkan Yumuk, Constantine Tsigos, Martin Fried, Karin Schindler, Luca Busetto, Dragan Micic, Hermann Toplak. Obes Facts 2015
324
11

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
11


A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.
Brian Finan, Bin Yang, Nickki Ottaway, David L Smiley, Tao Ma, Christoffer Clemmensen, Joe Chabenne, Lianshan Zhang, Kirk M Habegger, Katrin Fischer,[...]. Nat Med 2015
300
11

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
11

Long-term persistence of hormonal adaptations to weight loss.
Priya Sumithran, Luke A Prendergast, Elizabeth Delbridge, Katrina Purcell, Arthur Shulkes, Adamandia Kriketos, Joseph Proietto. N Engl J Med 2011
662
11

Semaglutide lowers body weight in rodents via distributed neural pathways.
Sanaz Gabery, Casper G Salinas, Sarah J Paulsen, Jonas Ahnfelt-Rønne, Tomas Alanentalo, Arian F Baquero, Stephen T Buckley, Erzsébet Farkas, Csaba Fekete, Klaus S Frederiksen,[...]. JCI Insight 2020
42
26

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
Andrew J Ahmann, Matthew Capehorn, Guillaume Charpentier, Francesco Dotta, Elena Henkel, Ildiko Lingvay, Anders G Holst, Miriam P Annett, Vanita R Aroda. Diabetes Care 2018
164
10


LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Tamer Coskun, Kyle W Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B Bokvist, Xuewei Cui, Daniel A Briere, Over Cabrera, William C Roell,[...]. Mol Metab 2018
100
10


Multicenter, placebo-controlled trial of lorcaserin for weight management.
Steven R Smith, Neil J Weissman, Christen M Anderson, Matilde Sanchez, Emil Chuang, Scott Stubbe, Harold Bays, William R Shanahan. N Engl J Med 2010
574
10

Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes.
Philip R Schauer, Deepak L Bhatt, John P Kirwan, Kathy Wolski, Ali Aminian, Stacy A Brethauer, Sankar D Navaneethan, Rishi P Singh, Claire E Pothier, Steven E Nissen,[...]. N Engl J Med 2017
10

Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.
Priscilla Hollander, Alok K Gupta, Raymond Plodkowski, Frank Greenway, Harold Bays, Colleen Burns, Preston Klassen, Ken Fujioka. Diabetes Care 2013
195
10

Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Rohan Khera, Mohammad Hassan Murad, Apoorva K Chandar, Parambir S Dulai, Zhen Wang, Larry J Prokop, Rohit Loomba, Michael Camilleri, Siddharth Singh. JAMA 2016
270
10

Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
Thomas A Wadden, John P Foreyt, Gary D Foster, James O Hill, Samuel Klein, Patrick M O'Neil, Michael G Perri, F Xavier Pi-Sunyer, Cheryl L Rock, Janelle S Erickson,[...]. Obesity (Silver Spring) 2011
260
9

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
9


The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.
Juan Pablo Frias, Edward J Bastyr, Louis Vignati, Matthias H Tschöp, Christophe Schmitt, Klara Owen, Rune Haubo Christensen, Richard D DiMarchi. Cell Metab 2017
121
9

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
A Astrup, R Carraro, N Finer, A Harper, M Kunesova, M E J Lean, L Niskanen, M F Rasmussen, A Rissanen, S Rössner,[...]. Int J Obes (Lond) 2012
327
9

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.
Erin A Bohula, Stephen D Wiviott, Darren K McGuire, Silvio E Inzucchi, Julia Kuder, KyungAh Im, Christina L Fanola, Arman Qamar, Conville Brown, Andrzej Budaj,[...]. N Engl J Med 2018
109
9

Health Effects of Overweight and Obesity in 195 Countries over 25 Years.
Ashkan Afshin, Mohammad H Forouzanfar, Marissa B Reitsma, Patrick Sur, Kara Estep, Alex Lee, Laurie Marczak, Ali H Mokdad, Maziar Moradi-Lakeh, Mohsen Naghavi,[...]. N Engl J Med 2017
9

Pharmacological management of obesity: an endocrine Society clinical practice guideline.
Caroline M Apovian, Louis J Aronne, Daniel H Bessesen, Marie E McDonnell, M Hassan Murad, Uberto Pagotto, Donna H Ryan, Christopher D Still. J Clin Endocrinol Metab 2015
466
9


A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
Meredith C Fidler, Matilde Sanchez, Brian Raether, Neil J Weissman, Steven R Smith, William R Shanahan, Christen M Anderson. J Clin Endocrinol Metab 2011
352
8

Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.
A Blackman, G D Foster, G Zammit, R Rosenberg, L Aronne, T Wadden, B Claudius, C B Jensen, E Mignot. Int J Obes (Lond) 2016
107
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.